Belantamab Mafodotin with Pomalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma: A Comprehensive Exposure-Response Analysis of the DREAMM-8 Study
Sign Up to like & getrecommendations! Published in 2025 at "Targeted Oncology"
DOI: 10.1007/s11523-025-01174-0
Abstract: In the phase 3 DREAMM-8 study (NCT04484623), belantamab mafodotin (anti-B-cell maturation antigen [BCMA] antibody-drug conjugate with a monomethyl auristatin F payload) with pomalidomide and dexamethasone (BPd) showed significant progression-free survival benefit in second-line or later… read more here.
Keywords: dreamm; response; belantamab; belantamab mafodotin ... See more keywords
The clinical journey of belantamab mafodotin in relapsed or refractory multiple myeloma: lessons in drug development
Sign Up to like & getrecommendations! Published in 2025 at "Blood Cancer Journal"
DOI: 10.1038/s41408-025-01212-0
Abstract: Patients with relapsed/refractory multiple myeloma (RRMM) have a poor prognosis and a need remains for novel effective therapies. Belantamab mafodotin, an anti–B-cell maturation antigen antibody-drug conjugate, was granted accelerated/conditional approval for patients with RRMM who… read more here.
Keywords: dreamm; mafodotin; refractory multiple; belantamab mafodotin ... See more keywords
DREAMM: a web-based server for drugging protein-membrane interfaces as a novel workflow for targeted drug design
Sign Up to like & getrecommendations! Published in 2022 at "Bioinformatics"
DOI: 10.1093/bioinformatics/btac680
Abstract: Abstract Summary The allosteric modulation of peripheral membrane proteins (PMPs) by targeting protein-membrane interactions with drug-like molecules represents a new promising therapeutic strategy for proteins currently considered undruggable. However, the accessibility of protein-membrane interfaces by… read more here.
Keywords: membrane interfaces; dreamm; membrane; drugging protein ... See more keywords
Belantamab mafodotin concentration–QTc relationships in patients with relapsed or refractory multiple myeloma from the DREAMM‐1 and ‐2 studies
Sign Up to like & getrecommendations! Published in 2024 at "British Journal of Clinical Pharmacology"
DOI: 10.1111/bcp.16133
Abstract: To evaluate relationships between plasma concentrations of belantamab mafodotin, total monoclonal antibody, and its payload and changes in electrocardiogram (ECG) parameters in patients with relapsed or refractory multiple myeloma from the DREAMM‐1 and DREAMM‐2 studies. read more here.
Keywords: dreamm; multiple myeloma; refractory multiple; belantamab mafodotin ... See more keywords
Real-World Patient Characteristics and Treatment Outcomes for Multiple Myeloma in Dreamm-7 and Dreamm-8 Cohorts in Finland
Sign Up to like & getrecommendations! Published in 2024 at "Blood"
DOI: 10.1182/blood-2024-209552
Abstract: Introduction: Belantamab mafodotin (belamaf) is a novel treatment option for advanced multiple myeloma (MM), for which numerous clinical trials are ongoing. This population-based study aimed to describe the characteristics and treatment outcomes of MM patients,… read more here.
Keywords: dreamm; treatment; like cohort; dreamm dreamm ... See more keywords
Impact of belantamab mafodotin–containing regimens on renal function in patients with Relapsed/Refractory multiple myeloma (RRMM) and mild/moderate renal impairment in the dreamm-7 and dreamm-8 trials
Sign Up to like & getrecommendations! Published in 2025 at "Blood"
DOI: 10.1182/blood-2025-2260
Abstract: Introduction: Renal impairment is a common clinical complication in patients with RRMM, and improvement in renal function is associated with better outcomes. In the ongoing phase 1 DREAMM-12 study (NCT04398745), belantamab mafodotin (belamaf) pharmacokinetics appeared… read more here.
Keywords: dreamm; improvement; function; renal impairment ... See more keywords
Patient-reported outcomes from dreamm-7 and dreamm-8 using the EQ-5D-3L, patient global impression of severity, and patient global impression of change
Sign Up to like & getrecommendations! Published in 2025 at "Blood"
DOI: 10.1182/blood-2025-5823
Abstract: Background: In DREAMM-7 (NCT04246047), belantamab mafodotin (belamaf) in combination with bortezomib and dexamethasone (BVd) demonstrated significant improvements in progression-free survival (PFS; median follow-up, 28.2 months; hazard ratio [HR], 0.41; 95% CI, 0.31-0.53; P read more here.
Keywords: dreamm; treatment; patient global; global impression ... See more keywords
Modification of belantamab mafodotin dosing to balance efficacy and tolerability in the DREAMM-7 and DREAMM-8 trials
Sign Up to like & getrecommendations! Published in 2025 at "Blood Advances"
DOI: 10.1182/bloodadvances.2025016949
Abstract: Key Points • Dose modifications in DREAMM-7 and DREAMM-8 led to less frequent belamaf dosing in later periods of treatment.• Ocular events were managed by belamaf dose modifications, which allowed for continuation of treatment and… read more here.
Keywords: dreamm; modification belantamab; efficacy; mafodotin dosing ... See more keywords